Thyrocare Technologies Bonus Shares: Record Date Out For 2:1 Free Shares; Check Allotment Details

The record date for bonus shares has been announced by Thyrocare Technologies, a publicly listed healthcare firm with headquarters in India. The corporation established a record date for evaluating shareholders' eligibility for the issue and distribution of 2:1 bonus shares based on a Board meeting that took place on November 16, 2025.

Thyrocare Technologies Bonus Shares Record Date

The Board of Directors' decision to issue bonus equity shares was previously communicated to the exchange by the company on October 14, 2025. On November 16, 2025, the firm further announced that the bonus issue had been officially authorized by the shareholders. The bonus shares will be issued in a 2:1 ratio, which means that for every current fully paid-up equity share with a face value of Rs 10, shareholders will get two bonus equity shares with a face value of Rs 10 each. A major step toward rewarding shareholders and improving liquidity, the bonus shares will rank pari-passu in every way and have the same rights as current shares.

"Pursuant to Regulation 42 of the SEBI Listing Regulations, we wish to inform you that the Company has fixed Friday, November 28, 2025, as the "Record Date" for determining the eligibility of shareholders for issuance and allotment of Bonus Shares. Further, in accordance with SEBI circular no. CIR/CFD/PoD/2024/122 dated September 16, 2024, the deemed date of allotment of Bonus Shares shall be Monday, December 1, 2025, and the said bonus shares will be made available for trading on the next working day of allotment i.e. Tuesday, December 2, 2025," said Thyrocare Technologies in a stock exchange filing.

Thyrocare Technologies Bonus Shares Details

As part of its bonus issue, the company has proposed issuing 10,61,07,794 bonus equity shares, each worth Rs 10. The ultimate amount may vary based on stock option exercises under the Thryocare Employee Stock Option Scheme by the record date. As of September 30, 2025, the bonus shares will be distributed by capitalizing amounts from the Securities Premium Account, Capital Redemption Reserve, Free Reserves, and/or Retained Earnings.

The company's issued, subscribed, and paid-up capital is Rs 53,05,38,970, which consists of 5,30,53,897 equity shares of Rs 10 each. Prior to the bonus issue, the company's authorized capital was Rs 1,00,00,00,000, split into 10 crore equity shares of Rs 10 each.

Based on unaudited financials as of September 30, 2025, capitalizing funds from the company's free reserves-including the Capital Redemption Reserve (Rs 0.96 crore), Securities Premium (Rs 78.09 crore), General Reserve (Rs 205.42 crore), and Retained Earnings (Rs 76.29 crore)-will be used to hand out these bonus shares. The company anticipates crediting or distributing the bonus shares within two months after the Board's approval, on or before December 13, 2025, subject to shareholder and regulatory clearances.

Thyrocare Technologies Target Price

"Thyrocare Technologies stock price is bearish & also overbought on the Daily charts with strong resistance at 1609. Investors should be booking profits as a Daily close below support of 1560 could lead to a target of 1399 in the near term," commented A R Ramachandran, Independent SEBI registered Research Analyst, Tips2trades.

"Thyrocare is stabilising after a steady uptrend. The price is holding above rising moving averages, indicating a healthy trend. Momentum indicators remain positive but slightly overextended. Support lies near ₹1,500. Sustained trade above ₹1,600 can open the path towards higher levels; dips remain buy-on-weakness opportunities," commented Riyank Arora, technical analyst at Mehta Equities Ltd.

Disclaimer: The views and recommendations expressed are solely those of the individual analysts or entities and do not reflect the views of Goodreturns.in or Greynium Information Technologies Private Limited (together referred to as "we"). We do not guarantee, endorse or take responsibility for the accuracy, completeness or reliability of any content, nor do we provide any investment advice or solicit the purchase or sale of securities. All information is provided for informational and educational purposes only and should be independently verified from licensed financial advisors before making any investment decisions.